TACI Polyclonal Antibody, Cy3 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-4841R-Cy3 |
| Product Name | TACI Polyclonal Antibody, Cy3 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human |
| Specifications | |
| Conjugation | Cy3 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human TNFRSF13B/TACI |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Cell membrane |
| Synonyms | TACI; CD267; CD267 antigen; CVID; TNFRSF 13B; TNFRSF 14B;TNFRSF13B; TNFRSF13B protein; TNFRSF14B; Transmembrane activator and CAML interactor; Tumor necrosis factor receptor 13B; Tumor necrosis factor receptor superfamily member 13B. |
| Background | TACI is a lymphocyte specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein binds to both APRIL and BAFF and induces activation of the transcription factors NFAT (nuclear-factor of activated T cells), AP1, and NF kappa B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith Magenis syndrome region on chromosome 17. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |